Skip to main content
Premium Trial:

Request an Annual Quote

IGA Licenses KeyGene's Sequence-based Genotyping Technology

NEW YORK (GenomeWeb) – IGA Techology Services has licensed KeyGene's sequence-based genotyping technology for use in certain fields, the firms said today.

As part of the deal, IGA has gained a non-exclusive license for the commercial offering and use of KeyGene's technology, which includes restriction-site-associated DNA sequencing, genotyping-by-sequencing, and related methods for discovering and scoring genetic markets without genome sequence information. The firms said that the technology provides a "very powerful" method of characterizing breeding germplasm diversity and developing markers for improving agronomic traits.

Financial and other terms of the agreement were not disclosed.

KeyGene CSO Michiel van Eijk said in a statement that the ability to carry out genetic biomarker discovery and genotyping simultaneously is gaining widespread use in "a huge range of species" and today's deal "accelerates the genetic improvement of our crops, farm animals, and microorganisms."

The Scan

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.

Tibetan Study Finds Adaptive Variant Influencing Skin Pigmentation

With a combination of phenotyping and genetic data, researchers document at PNAS a Tibetan-enriched enhancer variant influencing melanin synthesis and ultraviolet light response.

Domestication Linked to Nervous System Genes in Inbred Mouse Strains

Researchers highlighted more than 300 positively selected genes in domesticated mice, including genes linked to nervous system function or behavior in Genome Biology.

ALS Genetic Testing May Be Informative Across Age Ranges, Study Finds

Researchers in the journal Brain identified clinically actionable variants in a significant subset of older ALS patients, prompting them to point to the potential benefits of broader test use.